For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
News Release
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring a…
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing. That…
Blog
The unseen costs of banning PBM-owned pharmacies in Tennessee
Tennessee lawmakers recently passed the FAIR Rx Act, which would bar companies from owning pharmacies while also operating a pharmacy benefit manager (PBM) and…
Search Posts
The New York Post
Politicians Are Using Omicron as an Excuse to Return to their Autocratic Ways
Since the start of the pandemic, governors around the country have often struggled to appear to be doing something to stem COVID-19, regardless of whether…
City Journal
One Size Doesn’t Fit All
In a rebuke of the Biden administration, the Fifth Circuit Court of Appeals reaffirmed its stay of the Occupational Safety and Health Administration’s (OSHA) workplace…
The New York Post
A Reality Check on How we Handle COVID-19 Risks
COVID-19 is still with us. Cases are rising in Europe and to a smaller extent in this country. But the fact that SARS-CoV-2, the virus…
Letters
CEI Joins ATR Led Drug Price Control Coalition Letter
Dear Member of Congress: We write in opposition to the Democrat plan to impose price controls, a 95 percent excise tax, and inflation penalties on…
National Review
What’s Taking the FDA So Long on COVID Drug Molnupiravir?
On October 1, pharmaceutical companies Merck and Ridgeback Biotherapeutics announced that their investigational oral antiviral drug Molnupiravir reduced the risk of hospitalization or death…
New York Post
Letter Confirms Wuhan Lab’s COVID-19 Leak was Funded by US Taxpayers
The origin of the SARS-CoV-2 virus that causes COVID-19 remains unclear, but recent revelations reinforce the likelihood that the true source was a lab leak…
